Johnson & Johnson vs Walmart Inc.: Strategic Comparison

This in-depth comparison examines Johnson & Johnson and Walmart Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Johnson & Johnson on its own, evaluating Walmart Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Johnson & Johnson and Walmart Inc. is widest.

On the headline numbers, Johnson & Johnson reports annual revenue of $94.2B against $713.2B for Walmart Inc., while their respective market capitalizations stand at $390.0B and $845.6B. Johnson & Johnson is headquartered in United States and Walmart Inc. operates from United States, and those different home markets shape how each company competes.

Johnson & Johnson: J&J is one of only two U.S. Corporations holding an AAA credit rating from all three major rating agencies simultaneously. The second is Microsoft. That financial standing — rarer than most people realize — gave J&J the acquisition capability to spend $29.7 billion on Abiomed and Shockwave Medical within a 30-month window, funding both with debt at rates most companies cannot access. The AAA rating is a competitive weapon in healthcare M&A. The 2023 Kenvue spinoff ended 137 years of consumer health. Tylenol, Band-Aid, Neutrogena, Listerine — the brands that built J&J's public recognition — left the corporate structure in an IPO that valued the consumer unit at roughly $40 billion. What remained was a focused pharmaceutical and medical device company generating $88.821 billion in FY2024 net sales across its pharmaceutical and MedTech segments. The spinoff was not a divestiture of weakness. It was a concentration of strategic resources toward higher-margin, harder-to-imitate business lines. Darzalex, the multiple myeloma treatment developed with Genmab, is approaching $15 billion in annual peak sales potential. The drug demonstrates how J&J systematically converts third-party scientific discoveries into commercial blockbusters through its development and regulatory infrastructure. Genmab discovered the antibody; J&J built the clinical development program, secured the FDA approval, and deployed the global commercial organization to generate revenues that neither party could have reached independently. The $6.475 billion talc litigation settlement proposed in 2024 — if accepted by the required supermajority of claimants — would be the largest personal injury tort settlement in J&J's history. The Texas Two-Step bankruptcy strategy that J&J attempted twice and that two federal appellate courts rejected as bad-faith abuse ultimately gave way to a direct settlement approach.

Walmart Inc.: Walmart generates $713.2 billion in annual revenue with a net margin around 3.1 percent — meaning roughly $22 billion falls to the bottom line from a business that employs 2.1 million people and operates stores in formats ranging from neighborhood markets to 180,000-square-foot Supercenters. The thin margin isn't a weakness; it's a deliberate pricing strategy that has destroyed competitors for six decades. The business is changing faster than the store count suggests. Advertising revenue, marketplace fees, membership income from Walmart+ and Sam's Club, and fulfillment services have added high-margin layers to a model that used to earn money only one way. These adjacent revenue streams don't show up obviously in a $713 billion revenue number, but they show up in margins. Sam Walton opened the first Walmart in Rogers, Arkansas in 1962. By 1970 the company went public. By 2000 it was the largest company in the world by revenue. The supply chain infrastructure built over those decades — cross-docking distribution centers, direct vendor relationships, proprietary logistics data — is what makes the everyday-low-price promise financially sustainable rather than merely aspirational. The Flipkart acquisition in 2018 gave Walmart a meaningful position in Indian e-commerce. The Jet.com acquisition in 2016 for $3.3 billion accelerated U.S. E-commerce capability. Neither produced the returns originally projected, but both shifted Walmart's trajectory in markets that would have been difficult to enter organically.

Johnson & Johnson and Walmart Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Johnson & Johnson and Walmart Inc..

Johnson & Johnson business model: Abiomed's Impella heart pump family provides temporary mechanical circulatory support in cardiogenic shock and high-risk interventional cardiology procedures, generating premium pricing and strong clinical evidence supporting outcomes improvement that defends reimbursement despite cost-consciousness in cardiac care reimbursement policy. J&J has consistently and vigorously disputed the scientific and legal basis of these claims, commissioning independent laboratory analyses supporting the safety of its talc products, and maintains that multiple government regulatory agencies have confirmed talc safety. Yet Final approval remains pending, and any settlement failure that forces J&J back to individual litigation would re-introduce uncertainty and potential additional reserve charges. China MedTech Pricing Reform, through the Chinese government's national and provincial volume-based procurement (VBP) programs for medical devices, has created material pricing pressure on J&J's orthopaedic and cardiovascular device businesses. J&J's regulatory affairs infrastructure — spanning pharmaceutical New Drug Applications, biologic license applications, 510(k) clearances, premarket approvals for high-risk devices, and post-approval pharmacovigilance — represents human capital and process knowledge that takes generations to build at the depth required for simultaneous management of hundreds of active regulatory interactions globally.

Walmart Inc. business model: Walmart's revenue model is deceptively simple on the surface — buy stuff, sell stuff, repeat — but the economics underneath have shifted dramatically in the past five years. The company still makes most of its $713.2 billion from selling physical goods through physical stores. That hasn't changed. What's changed is what happens around those transactions. Start with the core: Walmart U.S. Generates roughly $460 billion in net sales annually. About 60% of that is grocery — milk, eggs, produce, frozen meals, cleaning supplies. The margins on grocery are thin, often below 20% gross. But grocery is the reason a family visits Walmart 4.2 times per month instead of once. Every trip past the produce aisle is a trip past pharmacy ($4 generics, vaccinations, health screenings), past general merchandise (where margins run 30-40%), past seasonal displays, past the impulse buys near checkout. Grocery is the loss leader that funds everything else. Sam's Club contributes approximately $90 billion through a different mechanism: membership fees. The $50-$110 annual fee from roughly 47 million members generates high-margin recurring revenue before a single item is scanned. The merchandise itself is sold at near-cost — the profit is in the membership, not the product. It's the Costco model, and Sam's Club has finally started executing it well after years of underperformance. Walmart International — about $120 billion — is a patchwork. Walmex in Mexico is a powerhouse, essentially the dominant retailer in the country. Canada is stable and profitable. China is complicated. India, through Flipkart and PhonePe, is a long-term bet on digital commerce in a market of 1.4 billion people where e-commerce penetration is still in single digits. Now here's where it gets interesting. Layered on top of the merchandise business are three high-margin revenue streams that barely existed five years ago: Walmart Connect — the advertising business — sells sponsored product placements, display ads, and now connected-TV inventory (via the VIZIO acquisition) to brands desperate to reach consumers at the moment of purchase. This business grew 37% in Q4 FY2026 and likely generates margins above 50%. For context: selling a $3 box of cereal might generate $0.15 in profit. Selling an ad to the cereal company that appears when a shopper searches "breakfast" on the Walmart app might generate $2-5 in pure margin. The math is significant. Walmart+ membership ($98/year) creates subscription revenue while locking in delivery habits. It's smaller than Amazon Prime — probably 20-30 million members versus Prime's 200+ million — but it's growing, and each member spends significantly more than non-members. Marketplace seller fees and Walmart Fulfillment Services generate commission and logistics revenue from third-party sellers who want access to Walmart's customer base without Walmart bearing inventory risk. The operating margins tell the real story: approximately 4-5% on $713 billion in revenue. That's about $28-35 billion in operating income. Sounds enormous until you realize that a 1% swing in gross margin — from a bad quarter of markdowns, or a spike in shrinkage, or a logistics cost overrun — wipes out $7 billion. The business runs on volume and velocity, not fat margins. Every efficiency gain matters. Every basis point of shrinkage reduction matters. That's why Walmart spends billions annually on supply chain automation, demand forecasting AI, and inventory management systems that most shoppers never see.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Johnson & Johnson stack up against those of Walmart Inc..

Johnson & Johnson competitive advantage: The decision required J&J to exit the segment that had built its public identity, a brand-equity sacrifice that few companies of comparable scale have had the strategic discipline to make. Manufacturing scale-up — the primary commercial constraint for CAR-T therapy, which requires patient-specific cell processing at sophisticated manufacturing facilities — is J&J's primary Carvykti execution priority, as supply constraints have historically limited the product's commercial ramp relative to its clinical demand signals. Biosense Webster's CARTO 3 electro-anatomical cardiac mapping system is installed across electrophysiology labs at leading cardiac centers globally and represents J&J's most durable device competitive moat — a capital equipment installation that generates long-term catheter and disposable consumable revenue streams and requires comprehensive physician training that creates genuine switching costs. The delay between Ottava's initial announcement and commercial availability has allowed Intuitive Surgical, Medtronic (Hugo system), CMR Surgical (Versius), and other robotics entrants to further entrench their hospital relationships and surgeon training ecosystems, increasing the competitive difficulty of Ottava's market entry. J&J's financial profile in its post-Kenvue form reflects the premium economics of a pharmaceutical and medical device enterprise operating at scale, with gross margin characteristics more typical of a specialty pharma company than a traditional diversified healthcare conglomerate. In surgical robotics — one of the highest-growth categories in medical devices — Intuitive Surgical's da Vinci system has built an installed base and training ecosystem that dominates soft tissue robotic surgery. J&J's competitive advantages in its post-Kenvue form are concentrated in the depth of its oncology pharmaceutical franchise, the technical moats of key MedTech platforms, and the institutional advantages conferred by its AAA credit profile and nearly 140-year regulatory relationship with the FDA. Multiple Myeloma Treatment Continuum Dominance is J&J's single most commercially distinctive pharmaceutical advantage. Biosense Webster's CARTO Installed Base represents MedTech's most durable competitive moat through a combination of capital equipment installation, physician training investment, and clinical data infrastructure. These switching costs sustain J&J's catheter and disposable consumable revenue streams across the product refresh cycles that periodically occur in any medical device category. No other dedicated healthcare company can execute transactions of this magnitude as easily, giving J&J a structural M&A advantage in acquiring innovative medical technology companies at premium valuations while maintaining financial discipline. The J&J Credo as Institutional Trust Asset creates commercially real advantages in healthcare professional relationships, health system procurement, and payor negotiations. Emerging Market Pharmaceutical Access and MedTech Penetration in India, Southeast Asia, the Middle East, and Latin America represent long-duration growth opportunities in markets where J&J's brand recognition in healthcare professional settings, established regulatory relationships, and distribution infrastructure provide structural advantages. Finally, the surgical robotics execution timeline for Ottava remains a wildcard: delay relative to Intuitive Surgical's continued da Vinci platform investment and Medtronic's Hugo system commercialization could permanently disadvantage J&J in a category expected to dominate elective surgical volumes through 2035. One who was not was a thirty-one-year-old man named Robert Wood Johnson, who had been working in the pharmaceutical and surgical supply trade in New York and who recognized in Lister's antiseptic surgery principles an enormous commercial opportunity: if antiseptic methods were going to be adopted in American surgery — and he believed they inevitably would be — then someone needed to manufacture the sterile dressings, sutures, and wound care materials that antiseptic surgery required, in a factory setting that could ensure consistent sterility at scale. As antiseptic surgery became standard American practice, demand for factory-produced sterile surgical supplies grew rapidly, and J&J was positioned as one of the few companies prepared to supply them at scale and with consistent quality. The Civil War-era Union Army supply contracts that had accelerated P&G's national brand reach had a parallel in J&J's history: during World War II, J&J supplied the U.S. Military with medical dressings, sutures, and surgical materials at enormous scale, establishing relationships with military medical personnel who became civilian physicians and hospital administrators in the postwar years and carried their familiarity with J&J's product standards into peacetime medical practice.

Walmart Inc. competitive advantage: Consider what it would actually take to replicate Walmart's position from scratch. You'd need to acquire or build 4,700 stores positioned within ten miles of 90% of the U.S. Population — that's roughly $200 billion in real estate alone, assuming you could find the locations. You'd need relationships with tens of thousands of suppliers willing to give you their lowest wholesale prices — which they won't, because your volume doesn't justify it yet. You'd need a distribution network of 210+ facilities with a private fleet of 12,000+ trucks. You'd need 2.1 million trained employees. You'd need sixty years of brand recognition among American households. Nobody is doing that. Not Amazon, not Costco, not any private equity consortium. The physical infrastructure is the advantage, and it's essentially unreplicable at this point. But the more interesting defensive asset is behavioral. Walmart has embedded itself into the weekly routine of American households in a way that's almost invisible. People don't "decide" to shop at Walmart the way they decide to buy a new iPhone or subscribe to Netflix. They just. Go. It's Tuesday, the fridge is empty, the Walmart is seven minutes away. That habitual, low-consideration purchase behavior is extraordinarily sticky. It doesn't require brand love or emotional loyalty — it requires proximity and price, both of which Walmart dominates. The grocery frequency creates a data advantage that compounds over time. Walmart sees what 240 million people buy every week — not what they browse or click, but what they actually put in their cart and take home. That purchase data is gold for the advertising business, for demand forecasting, for private-label development, and for supplier negotiations. Amazon has browsing data and delivery data, but Walmart has in-store basket data at a scale nobody else touches. The store network also functions as a fulfillment advantage that pure e-commerce players can't match for perishable goods. You can't ship bananas from a centralized warehouse 800 miles away. You need local inventory, cold chain, and same-day capability. Walmart has all three, already built, already staffed, already stocked — in 4,700 locations. Amazon is spending billions trying to build grocery delivery infrastructure that Walmart inherited from decades of supercenter expansion.

Future prospects matter as much as current results. The growth strategies below explain how Johnson & Johnson and Walmart Inc. each plan to expand from here.

Johnson & Johnson growth strategy: That single year of R&D investment exceeded the total annual revenues of most pharmaceutical companies operating anywhere on earth. Today, J&J is a fundamentally different company than the consumer-focused healthcare conglomerate that defined its twentieth-century identity. The 2023 spinoff of Kenvue — which transferred Tylenol, Band-Aid, Neutrogena, Johnson's Baby, Listerine, Aveeno, Nicorette, and dozens of other iconic consumer brands to a separately traded public company — transformed J&J into a focused pharmaceutical and medical technology enterprise operating two clearly defined segments: novel Medicine and MedTech. The strategic question for CEO Joaquin Duato and his leadership team is whether J&J's oncology and MedTech innovation engines can generate the growth velocity needed to not merely offset Stelara's biosimilar-driven revenue decline but to accelerate beyond it — and whether the company's post-consumer transformation delivers the premium valuation multiple that pure-play pharmaceutical and device peers command in capital markets. The 2023 spinoff of the consumer health business as Kenvue (NYSE: KVUE) transformed J&J into a focused healthcare enterprise. Both businesses depend on sustained R&D investment, deep regulatory expertise accumulated over nearly 140 years of FDA-regulated product development, and professional relationships with physicians, hospitals, and payors — but they differ substantially in revenue predictability, margin structure, patent cycle pattern, competitive intensity, and capital requirements. The problem is, as each J&J-sponsored trial expands Darzalex's approved uses to progressively earlier lines of myeloma treatment, the drug's addressable patient population and usage duration grow continuously without requiring discovery of new patients. J&J is pursuing Carvykti's approval in earlier myeloma lines, with pivotal data supporting frontline use that could dramatically expand the patient population and commercial opportunity. Tremfya (guselkumab), an IL-23 p19 inhibitor approved for psoriasis and psoriatic arthritis with a differentiated mechanism from IL-17 inhibitors, serves as Stelara's partial succession brand and is growing steadily. The drug is growing substantially in annual revenue as more depression treatment centers establish certified administration programs, and represents J&J's primary commercial presence in the large, historically underserved, and increasingly well-reimbursed mental health treatment market. The resulting enterprise — focused entirely on novel Medicine and MedTech — carries a higher margin profile, a more pharmaceutical-intensive growth trajectory, and a more concentrated strategic risk than the legacy diversified J&J. AbbVie's Skyrizi (risankizumab, IL-23 inhibitor) and Rinvoq (upadacitinib, JAK1 inhibitor) are growing rapidly in psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis — the exact same indications as J&J's Tremfya and the biosimilar-pressured Stelara. Abbott's pulsed field ablation catheter (Volt PFA, pending U.S. Approval at the time of this writing) is the most significant competitive threat to J&J's Varipulse PFA system, as both companies are launching next-generation ablation technology simultaneously in a rapidly growing market for atrial fibrillation ablation. J&J's orthopaedic robotics strategy centers on the Velys robotic surgical system for total knee arthroplasty, which J&J launched and has been expanding commercially, though Stryker's Mako first-mover advantage in robotics has been difficult to offset through a later-entry competitive system. J&J's Ottava surgical robotic system, designed to compete in open and minimally invasive abdominal surgery, is in active development, clinical validation, and initial commercial launch. The spread between GAAP and adjusted EPS reflects the reality that J&J is simultaneously managing an acquisition-intensive growth strategy (which creates significant acquisition-related amortization) and a major legal resolution (talc), both of which create accounting charges unrelated to the underlying operating cash generation of the business. Return on invested capital consistently runs in the 18 to 25 percent range across the combined business, reflecting the premium economics of both pharmaceutical patent-protected revenue and device platform-anchored MedTech revenues. Management has guided investors that growth in Darzalex, Tremfya, Spravato, and new pipeline launches will offset the Stelara headwind over a multi-year period, but the transition creates a near-term revenue and earnings growth gap that requires precise timing in the commercial launch cadence of next-generation assets. Investors and equity analysts have been skeptical that the bridge period — fiscal 2025 through 2026 — can be navigated without reported revenue declining in the novel Medicine segment, creating potential pressure on J&J's share price and making the Stelara cliff the most frequently cited near-term risk in J&J equity research. China represented a historically growing and profitable geography for J&J's medical device businesses; VBP programs have materially reduced the revenue contribution from this market and forced J&J to restructure its China MedTech commercial strategy toward higher-technology products less subject to commoditized procurement. The VBP program is expanding to cover additional device categories over time, creating ongoing structural pricing headwinds in one of J&J's most important international device markets. This treatment-continuum positioning means that J&J's total addressable commercial opportunity within the myeloma disease area grows with every line-extension approval even without new patient diagnoses — as Darzalex expands into maintenance therapy, as Carvykti moves into earlier lines, and as Talvey captures post-Darzalex patients. Building an equivalent multi-asset myeloma franchise from scratch would require 15 to 20 years of research investment and multiple successful Phase 3 programs — a barrier that gives J&J a durable competitive position in the world's most commercially developed blood cancer indication. The company's track record with regulatory agencies worldwide creates a presumption of competence in clinical data package quality and manufacturing validation that accelerates review timelines at the margin. J&J's growth strategy under CEO Joaquin Duato is organized around four reinforcing priorities: oncology franchise deepening, MedTech platform innovation, strategic bolt-on acquisitions funded by the AAA balance sheet, and geographic market development in high-growth emerging healthcare markets. The strategic logic is straightforward: J&J already commands multiple myeloma's treatment standard across multiple lines and mechanisms; the growth lever is systematic expansion of each asset's approved use into progressively earlier disease stages where patient populations are larger and treatment duration is longer. Carvykti's ongoing clinical program to support frontline CAR-T use, if approved, would represent a transformational label expansion: moving from use in fifth-line patients with median survival measured in months to use in first-line patients with decade-long survival potential, dramatically expanding both patient eligibility and commercial duration per patient. MedTech Platform Innovation Strategy centers on establishing or extending leadership positions in the three fastest-growing device categories: cardiac electrophysiology and ablation, mechanical circulatory support, and minimally invasive surgical robotics. In electrophysiology, Varipulse PFA is J&J's primary innovation investment, designed to capture the market transition from radiofrequency and cryoablation toward pulsed field energy — a technology believed to offer faster procedures and improved safety profiles that will expand the total AF ablation market by bringing more patients to treatment. In surgical robotics, Ottava's commercial execution represents both the most significant strategic investment and the most complex execution challenge in the MedTech pipeline. Pharmaceutical penetration of oncology treatments in markets where cancer diagnoses are growing but specialist infrastructure and reimbursement systems are developing represents both a commercial opportunity and a public health mission aligned with the J&J Credo's prioritization of patient access. J&J's medium-term outlook presents a clearly structured transition narrative with defined near-term headwinds and credible long-term growth catalysts, making it one of the more analytically legible large-cap pharmaceutical investment situations. The bull case for J&J rests on the compound growth potential of its oncology franchise, the clinical validation of MedTech platform innovations, and the financial flexibility of its AAA balance sheet. The pipeline of bispecific antibodies — Talvey, Rybrevant (amivantamab for EGFR-mutant NSCLC), and multiple compounds in clinical development — positions J&J for continued oncology growth beyond the currently approved franchise. If Stelara's U.S. Biosimilar erosion is faster and deeper than management guidance — which some analysts and payors' formulary teams suggest is possible given the competitive pattern of biosimilar market entry — and if next-generation assets (Tremfya, Spravato, new oncology launches) ramp more slowly than planned, J&J could face a period of reported revenue and earnings decline in fiscal 2025 to 2026 that would pressure its valuation multiple. Robert Wood Johnson spent the decade following the Philadelphia Exposition building the practical knowledge and commercial relationships needed to execute on this insight. American medicine's acceptance of antiseptic surgery principles accelerated through the late 1880s and 1890s, driven by the demonstrably superior outcomes of surgeons who adopted Listerian technique — survival rates that contemporary physicians documented with sufficient clarity to overcome even organized professional skepticism. Johnson II transformed J&J from a surgical supply manufacturer into the diversified healthcare conglomerate that it would remain for most of the twentieth century — acquiring consumer product businesses, establishing pharmaceutical divisions, and building international operations. Initial sales were modest — the first-year production run was sold almost entirely to the Boy Scouts of America — but as J&J's marketing team improved the product's design and expanded distribution, Band-Aid grew into one of the most recognizable consumer product brand names in the world, a designation it maintained for a century before moving to Kenvue in the 2023 consumer separation.

Walmart Inc. growth strategy: Walmart's growth bet is straightforward, even if the execution is brutally complex: use the weekly grocery trip as a platform to sell higher-margin services. Advertising is the crown jewel. Walmart Connect grew 37% in Q4 FY2026, and management has signaled this is still early innings. The logic is compelling — brands have always paid for shelf placement in physical stores (those end-cap displays aren't free), and now they'll pay for digital shelf placement too. The VIZIO acquisition in 2024 added connected-TV advertising to the mix, meaning Walmart can now sell ads that follow a shopper from their living room TV to the Walmart app to the in-store digital display. That closed-loop attribution is what advertisers crave, and it's something only retailers with massive first-party purchase data can offer. Marketplace expansion is the volume play. Walmart.com now hosts hundreds of thousands of third-party sellers, dramatically expanding the product catalog without requiring Walmart to buy or warehouse inventory. Each seller pays referral fees (typically 6-15%), and many pay for Walmart Fulfillment Services and Walmart Connect ads on top of that. The flywheel is obvious: more sellers means more selection, which means more shoppers, which attracts more sellers. Automation is the cost play. Online grocery delivery is currently unprofitable at scale — the labor cost of picking, packing, and delivering a $120 grocery order eats the margin entirely. Walmart is investing heavily in automated micro-fulfillment centers inside existing stores, where robots pick ambient and refrigerated items while human associates handle produce and fragile goods. The goal is to cut the cost-per-order for e-commerce fulfillment by 30-50% over the next three years. The international portfolio is selective. Flipkart in India is the big swing — a market where 900 million people will come online as shoppers over the next decade. Walmex in Mexico is the steady compounder. Everything else is either stable (Canada) or being managed for returns rather than growth (China, Chile). Notably absent from this strategy: dramatic store expansion in the U.S. Walmart isn't building hundreds of new supercenters. The 4,700 existing U.S. Stores are the infrastructure. The strategy is to extract more revenue and profit per square foot from what already exists.

A closer look at the financial trajectory of Johnson & Johnson and Walmart Inc. rounds out the comparison.

Johnson & Johnson: FY2024 net sales of $88.821 billion declined from the $93.775 billion reported in FY2021 and FY2022 — the comparison is complicated by the Kenvue spinoff in 2023, which removed the consumer health segment's revenue from the consolidated results. The post-spinoff J&J generates $88.821 billion from pharmaceuticals and medical devices rather than the pre-spinoff total that included consumer products. Net income of $13.3 billion on $88.821 billion in revenue implies a 15% net margin — high for a diversified healthcare company and reflecting the pricing power of drugs like Darzalex and Stelara, which commands premium reimbursement from payers based on clinical evidence that is difficult to challenge. The $6.475 billion talc settlement, if approved, will be a significant one-time charge but eliminates the open-ended litigation overhang that has compressed J&J's valuation multiple for years. Resolving the talc liability removes uncertainty that is more damaging to valuation than the settlement amount itself. Market capitalization of $390 billion at roughly 4.4x revenue reflects the pharmaceutical growth profile — Darzalex approaching peak sales, the MedTech MedTech pipeline including Shockwave Medical's cardiovascular technology, and the AAA-rated acquisition capacity to add the next growth driver when the current portfolio matures. The pharmaceutical segment's gross margin profile, driven by patent-protected specialty drugs, is what justifies the premium multiple over the consolidated revenue base.

Walmart Inc.: Revenue grew from $611.3 billion in fiscal 2023 to $713.2 billion in fiscal 2026, a pace that represents roughly $100 billion in additional annual revenue over three years — a figure larger than most Fortune 500 companies' total revenues. Grocery volume, U.S. E-commerce growth, Sam's Club membership expansion, and the international segment all contributed. The $845.6 billion market capitalization against $713.2 billion in revenue implies a price-to-sales multiple above one — a premium to what a pure grocer would command, reflecting the market pricing in the advertising, marketplace, and membership businesses as higher-multiple growth assets embedded inside the retail operation. The net income figure is not separately disclosed in the available data, but at a 3.1 percent margin on $713.2 billion, the implied earnings are substantial in absolute terms while modest as a percentage. That combination — large absolute earnings, thin margins — is exactly the arithmetic that makes Walmart's competitive position so durable. Matching its pricing requires matching its cost structure, which requires matching its volume, which is circular. Advertising revenue is the financial development worth watching closely over the next decade. Walmart Connect, the advertising platform, operates at margins that bear no resemblance to retail. Every transaction in every store and on Walmart.com generates data about what customers buy, when, and at what price — data that consumer goods companies will pay significant fees to target precisely.